Loading…
Burning Rock Biotech Limited is projected to decline to $11.01 by 2027, a -3% move from its current price of $11.30. BNR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.69 | $11.30 | $11.95 | +0.01% |
| Jul 14 | $10.45 | $11.30 | $12.22 | +0.01% |
| Jul 15 | $10.27 | $11.30 | $12.44 | +0.02% |
| Jul 16 | $10.12 | $11.30 | $12.63 | +0.02% |
| Jul 17 | $9.98 | $11.30 | $12.80 | +0.03% |
| Jul 18 | $9.87 | $11.30 | $12.95 | +0.04% |
| Jul 19 | $9.76 | $11.30 | $13.09 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.76 | $11.30 | $13.09 | +0.04% |
| Week 2 | $9.19 | $11.31 | $13.92 | +0.09% |
| Week 3 | $8.77 | $11.31 | $14.59 | +0.13% |
| Week 4 | $8.44 | $11.32 | $15.18 | +0.18% |
| Week 5 | $8.16 | $11.32 | $15.72 | +0.22% |
| Week 6 | $7.91 | $11.33 | $16.23 | +0.26% |
| Week 7 | $7.69 | $11.33 | $16.71 | +0.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People’s Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits.
The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People’s Republic of China.
Burning Rock Biotech Limited trades as a healthcare-focused entity offering cancer therapy selection tests. The stock is currently priced at $11.75 per share and has a market capitalization of $123.92M, with a rank of 4101.
Looking ahead, the forecast presents a neutral stance in 2026 and 2027, followed by a bullish outlook from 2028 onward as average prices rise and upside potential expands. The forecasted path shows the average price climbing from $11.75 in 2026 to progressively higher levels through 2050, with notable gains reflected in later years.
A major floor 52.9% below — a decisive break under it would weaken the trend.
The nearest floor, 37.7% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 108.3% above — clearing it would confirm fresh momentum.
Key BNR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.16 | Buy | $11.02 | Buy |
| MA 10 | $9.93 | Buy | $10.30 | Buy |
| MA 20 | $8.98 | Buy | $9.94 | Buy |
| MA 50 | $11.96 | Sell | $11.91 | Sell |
| MA 100 | $16.43 | Sell | $14.63 | Sell |
| MA 200 | $17.69 | Sell | $15.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.78 | Neutral |
| Stoch RSI (14) | 88.30 | Sell |
| CCI (20) | 131.51 | Buy |
| Williams %R (14) | -10.74 | Info |
| MACD (12,26,9) | 0.67 | Buy |
| ROC (12) | 49.47 | Buy |
| Bollinger %B (20,2) | 0.91 | Neutral |
| Stochastic %K (14) | 89.26 | Sell |
| TRIX (15) | -1.10 | Sell |
| Awesome (5,34) | 1.53 | Buy |
| Ultimate (7,14,28) | 81.38 | Sell |
| Momentum (10) | 3.35 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 12.16 | Sell |
| ADX (14) | 26.19 | Buy |
| ATR (14) | 0.53 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) stands at 60, with the 50-day simple moving average at $12.21 and the 200-day simple moving average at $17.66.
Price support is positioned at $7.04 and resistance at $14.31, with the 30-day trading range between $7.99 and $17.28. Historical volatility remains high, with annualized volatility around 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.04 | $11.30 | $13.85 | 0% | Neutral | |
| $7.99 | $11.01 | $16.41 | -3% | Neutral | |
| $9.30 | $13.62 | $21.63 | +21% | Bullish | |
| $11.14 | $17.18 | $28.65 | +52% | Bullish | |
| $11.21 | $18.13 | $31.47 | +60% | Bullish | |
| $9.29 | $15.71 | $28.23 | +39% | Bullish | |
| $9.50 | $16.76 | $31.05 | +48% | Bullish | |
| $9.18 | $16.86 | $32.11 | +49% | Bullish | |
| $9.00 | $17.19 | $33.57 | +52% | Bullish | |
| $12.94 | $25.70 | $51.34 | +127% | Bullish | |
| $12.35 | $27.44 | $60.24 | +143% | Bullish | |
| $19.98 | $44.39 | $102.10 | +293% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.04 | $11.30 | $13.42 | +0.00% |
| August 2026 | $9.32 | $11.30 | $14.26 | -0.02% |
| September 2026 | $9.25 | $11.36 | $14.65 | +0.59% |
| October 2026 | $8.29 | $10.31 | $13.52 | -9.24% |
| November 2026 | $7.80 | $9.81 | $13.04 | -4.92% |
| December 2026 | $8.10 | $10.28 | $13.85 | +4.83% |
Click any year to see its month-by-month BNR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BNR to range from $7.04 to $13.85 through 2026. The $11.30 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BNR price prediction for 2027 points to an average of $11.01 (low $7.99, high $16.41) — a potential decline of -3% on today's $11.30. Price action looks broadly range-bound.
In 2028, BNR is projected to trade between $9.30 and $21.63, averaging $13.62 — a potential gain of +21% from today's $11.30. That is up +24% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Burning Rock Biotech Limited's 2029 outlook centres on $17.18, within a $11.14 to $28.65 range. That is up +26% on the projected 2028 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2030, BNR could reach as high as $31.47, with a base case around $18.13 and support toward $11.21 — roughly +60% from $11.30. Buyers look set to stay in control over this stretch.
Expect BNR to range from $9.29 to $28.23 through 2031. The $15.71 average target implies a +39% move from current prices. That is -13% versus the projected 2030 average. Momentum favours further upside here.
The BNR price prediction for 2032 points to an average of $16.76 (low $9.50, high $31.05) — a potential gain of +48% on today's $11.30. Buyers look set to stay in control over this stretch.
In 2033, BNR is projected to trade between $9.18 and $32.11, averaging $16.86 — a potential gain of +49% from today's $11.30. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Burning Rock Biotech Limited's 2034 outlook centres on $17.19, within a $9.00 to $33.57 range. That is up +2% on the projected 2033 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BNR could reach as high as $51.34, with a base case around $25.70 and support toward $12.94 — roughly +127% from $11.30. Momentum favours further upside here.
Expect BNR to range from $12.35 to $60.24 through 2040. The $27.44 average target implies a +143% move from current prices. That is up +7% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BNR price prediction for 2050 points to an average of $44.39 (low $19.98, high $102.10) — a potential gain of +293% on today's $11.30. Momentum favours further upside here.
Investing $1,000 in BNR today (≈ 88.495575 BNR) could be worth
$3,928.5
+$2,928.5 (+293%) by 2050 · US Dollar
Based on the average projected BNR price of $44.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNRwould be worth at today's price.
$1,000 invested in BNR on Jul 10, 2025 (≈ 251.25628 BNR) would be worth
$2,839.2
+$1,839.2 (+183.9%) today · 2.84× · US Dollar
Based on a BNR entry price of $3.98 vs. today's $11.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.82 | $1,150.71 | +15.1% |
| 1 month ago | $8.33 | $1,356.54 | +35.7% |
| 3 months ago | $15.85 | $713.16 | -28.7% |
| 6 months ago | $23.45 | $481.94 | -51.8% |
| 1 year ago | $3.98 | $2,839.2 | +183.9% |
| All time (5.0y) ago | $269.2 | $41.98 | -95.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNR forecast.
Our base-case forecast reaches $23.00 around 2035.
Implied market cap at $23.00: $202.72M
The multi-year forecast shows a bullish trajectory beginning in 2028, with the average price rising from $15.05 in 2028 to $50.99 in 2050 and an ultimate upside of 334% by 2050. In 2028 the average is $15.05 with a 28.1% upside; by 2029 the average is $18.82 with a 60.2% upside, and by 2030 the average is $19.69 with a 67.6% upside. The forecast remains bullish through 2031–2034, with 2035 projecting an average of $29.24 and a 148.8% upside, then continuing higher to 2040 at an average of $32.15 with a 173.6% upside and finally to 2050 with an average of $50.99 and a 334% upside.
In the near term, 2026 shows an average of $11.75 with 0% ROI and neutral sentiment, and 2027 shows an average of $11.69 with a -0.5% ROI and neutral sentiment. The later years carry a bullish sentiment, reflecting higher expected prices and returns, but these are estimates and not guarantees.
Tap a question to reveal the answer.
2030 forecast: min $12.17, avg $19.69, max $34.19, ROI 67.6%, sentiment BULLISH.
Forecasts show neutral in 2026 and 2027, followed by a bullish trend from 2028 onward, with average prices rising and ROI reaching up to 334% by 2050.
Yes. The 2050 forecast lists a max of $117.28, indicating the possibility of surpassing $100 by 2050.
2028 forecast: min $10.27, avg $15.05, max $23.91, ROI 28.1%, sentiment BULLISH.
Current price is $11.75 and market cap is $123.92M; the rank is 4101.
Burning Rock Biotech Limited Community Discussion
0Share your Burning Rock Biotech Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.